Literature DB >> 24874054

How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.

Edoardo Francini1, Giandomenico Roviello.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24874054     DOI： 10.1007/s13277-014-2145-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


× No keyword cloud information.
  3 in total

1.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

2.  Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.

Authors:  Andres Jan Schrader; Martin Boegemann; Carsten-H Ohlmann; Thomas J Schnoeller; Laura-Maria Krabbe; Turkan Hajili; Florian Jentzmik; Michael Stoeckle; Mark Schrader; Edwin Herrmann; Marcus V Cronauer
Journal:  Eur Urol       Date:  2013-07-02       Impact factor: 20.096

3.  Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Authors:  Carmel J Pezaro; Aurelius G Omlin; Amelia Altavilla; David Lorente; Roberta Ferraldeschi; Diletta Bianchini; David Dearnaley; Christopher Parker; Johann S de Bono; Gerhardt Attard
Journal:  Eur Urol       Date:  2013-12-17       Impact factor: 20.096
  3 in total
  1 in total

Review 1.  Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials.

Authors:  Giandomenico Roviello; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Alberto Bottini; Andrea Ravelli; Alberto Bonetta; Giovanni Paganini; Daniele Generali
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.